Novel diagnostics and therapeutics for people with genetic cholesterol disorders at risk for heart disease
Lipid Genomics is developing its FDA-approved investigational drug targeted at people with variations in the HDL ("good cholesterol") SCARB1 gene. More than 117 million people in the US could benefit from this drug. Lipid Genomics has a potential to generate a very sizeable profit as the market size for this therapeutic is $2.8 billion and for their second product, a novel immune checkpoint inhibitor, lymphocyte activation gene-3 (LAG-3) the market size is $1.4 billion.
Annabelle Rodriguez-Oquendo, Ph.D./ Founder
Mr. Gerard C. Smith, CEO